Financial Performance and Guidance - Cardinal Health raises its fiscal year 2026 non-GAAP diluted EPS guidance to at least $10.00, up from the previous range of $9.65 to $9.85[5] - The company anticipates approximately $3.4 billion in operating earnings for fiscal year 2026[19] - Cardinal Health expects approximately $3.25 billion in adjusted free cash flow for fiscal year 2026[20] Specialty Growth - Specialty revenue is projected to exceed $50 billion in fiscal year 2026, representing a 16% compound annual growth rate (CAGR) over three years[5, 35] - BioPharma Solutions is expected to grow over 30% in fiscal year 2026[37, 45] - Cardinal Health's MSOs contribute approximately $4.5 billion in higher-margin revenue[42] Strategic Initiatives - Cardinal Health is introducing ContinuCare Pathway to simplify diabetes supply management for pharmacies and patients, partnering with Publix Super Markets Inc[7] - The company is prioritizing growth in therapeutic areas such as autoimmune, urology, and oncology[37] - Cardinal Health aims to achieve $1 billion in higher-margin revenue from BioPharma Solutions by fiscal year 2028[43] Overall Strategy - Cardinal Health is focused on simplification, expanding in Specialty, accelerating other growth businesses, and executing GMPD Improvement Plan initiatives[34] - The company highlights a consistent track record, unique breadth of capabilities, and a resilient business model[57]

Financial Performance and Outlook - The company is targeting a 12% to 14% non-GAAP EPS CAGR [22, 72, 325, 369]. - The company expects to generate approximately $9 billion in adjusted free cash flow (FCF) [19]. - The company is raising FY25 EPS guidance to $8.15 - $8.20 [22, 311]. - The company provides FY26 EPS guidance for ~13% growth [22, 328]. - The company anticipates generating $10B+ in total adjusted free cash flow over the next 3 years [347]. Segment Performance and Strategy - Pharma segment profit growth is expected to be 8% CAGR [19]. - Other segment profit growth is expected to be 10% CAGR [19]. - Specialty is now over $40B in revenue, growing at a 14% CAGR over the last 3 years [104]. - GMPD delivered $92M of segment profit in FY24, a ~$240M increase over FY23 [278]. - The company is investing over $150M in NPHS over the next three years [53].